Display options
Cite
Kapelouzou A, Tsourelis L, Kaklamanis L, et al. Serum and tissue biomarkers in aortic stenosis. Glob Cardiol Sci Pract. 2015;2015(4):49doi: 10.5339/gcsp.2015.49.
Kapelouzou, A., Tsourelis, L., Kaklamanis, L., Degiannis, D., Kogerakis, N., & Cokkinos, D. V. (2015). Serum and tissue biomarkers in aortic stenosis. Global cardiology science & practice, 2015(4), 49. https://doi.org/10.5339/gcsp.2015.49
Kapelouzou, Alkistis, et al. "Serum and tissue biomarkers in aortic stenosis." Global cardiology science & practice vol. 2015,4 (2015): 49. doi: https://doi.org/10.5339/gcsp.2015.49
Kapelouzou A, Tsourelis L, Kaklamanis L, Degiannis D, Kogerakis N, Cokkinos DV. Serum and tissue biomarkers in aortic stenosis. Glob Cardiol Sci Pract. 2015 Nov 13;2015(4):49. doi: 10.5339/gcsp.2015.49. eCollection 2015. PMID: 26779524; PMCID: PMC4710866.
Copy Download .nbib Format: NLM
Share it on

Glob Cardiol Sci Pract. 2015 Nov 13;2015(4):49. doi: 10.5339/gcsp.2015.49. eCollection 2015.

Serum and tissue biomarkers in aortic stenosis.

Global cardiology science & practice

Alkistis Kapelouzou, Loukas Tsourelis, Loukas Kaklamanis, Dimitrios Degiannis, Nektarios Kogerakis, Dennis V Cokkinos

Affiliations

  1. Center of Clinical, Experimental Surgery, & Translation Research. Biomedical Research Foundation Academy of Athens (BRFAA), Soranou Efesiou 4 11527Athens, Greece.
  2. Department of Pathology, Onassis Cardiac Surgery Center, Avenue Sygrou 356 17674Athens, Greece.
  3. Laboratory of Molecular Immunopathology and Istocompatibility Onassis Cardiac Surgery Center, Avenue Sygrou 356 17674Athens, Greece.

PMID: 26779524 PMCID: PMC4710866 DOI: 10.5339/gcsp.2015.49

Abstract

BACKGROUND: Calcific aortic valve stenosis (CAVS) is seen in a large proportion of individuals over 60 years. It is an active process, influenced by lipid accumulation, mechanical stress, inflammation, and abnormal extracellular matrix turnover. Various biomarkers (BMs) are studied, as regards mechanisms, diagnosis and prognosis.

METHODS: In the calcified valves calcium deposition, elastin fragmentation and disorganization of cellular matrix were assessed, together with expression of OPN, OPG, osteocalcin (OCN) and RL2. We prospectively studied the following serum BMs in 60 patients with CAVS and compared them to 20 healthy controls, free from any cardiac disease: Matrix metalloproteinases (MMP) 2 and 9 and tissue inhibitor of metalloproteinase 1 (TIMP1), which regulate collagen turnover, inflammatory factors, i.e. tumor necrosis factor a (TNFa), interleukin 2 (IL2), transforming growth factor β1 (TGF-β1) which regulates fibrosis, fetuin-A (fet-A), osteopontin (OPN), osteoprotegerin (OPG), sclerostin (SOST), and relaxin-2 (RL2) which positively or negatively regulate calcification. Monocyte chemoattractant protein 1 (MCP-1) which regulates migration and infiltration of monocytes/macrophages was also studied as well as malondialdehyde (MDA) an oxidative marker.

RESULTS: Extent of tissue valve calcification (Alizarin Red stain) was negatively correlated with tissue elastin, and RL2, and positively correlated with tissue OCN and serum TIMP1 and MCP-1 and negatively with MMP9. Tissue OCN was positively correlated with OPN and negatively with the elastin. Tissue OPN was negatively correlated with elastin and OPG. Tissue OPN OPG and RL2 were not correlated with serum levels In the serum we found in patients statistically lower TIMP1, fet-A and RL2 levels, while all other BMs were higher compared to the healthy group. Positive correlations between SOST and IL2, OPG and MDA but negative with TNFa and OPN were found; also MMP9 was negatively correlated with TNFa and MCP-1 was negatively correlated with TIMP1.

CONCLUSION: We found that many BMs expressing calcification, collagen breakdown, or formation, and inflammation are increased in the valve tissue and in the serum of patients with CAVS as compared with healthy group. Our findings may give new insights towards diagnosis but also therapy. Thus antisclerostin, and antiflammatory agents could be tried for preventing aortic calcification progression.

Keywords: Sclerostin; aortic valve stenosis; biomarkers; calcification; relaxin-2

References

  1. J Mol Cell Cardiol. 2008 Dec;45(6):821-31 - PubMed
  2. J Am Coll Cardiol. 1993 Apr;21(5):1220-5 - PubMed
  3. J Heart Valve Dis. 2013 May;22(3):317-25 - PubMed
  4. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):708-15 - PubMed
  5. J Am Coll Cardiol. 1994 Apr;23(5):1162-70 - PubMed
  6. Springerplus. 2013 Dec 06;2:658 - PubMed
  7. Glob Cardiol Sci Pract. 2014 Jan 29;2014(1):52-77 - PubMed
  8. Heart. 2002 Oct;88(4):348-51 - PubMed
  9. J Cell Biol. 1997 Oct 6;139(1):279-93 - PubMed
  10. Can J Cardiol. 2007 Oct;23 Suppl B:32B-39B - PubMed
  11. Vasc Health Risk Manag. 2007;3(5):673-89 - PubMed
  12. J Am Coll Cardiol. 2008 Oct 14;52(16):1314-25 - PubMed
  13. J Heart Valve Dis. 2013 Mar;22(2):156-65 - PubMed
  14. Hellenic J Cardiol. 2007 Jan-Feb;48(1):5-14 - PubMed
  15. J Thorac Cardiovasc Surg. 2011 Oct;142(4):895-901 - PubMed
  16. J Endocrinol Invest. 2009;32(4 Suppl):6-9 - PubMed
  17. Circ Res. 2011 May 27;108(11):1392-412 - PubMed
  18. Circ Res. 2013 Jul 5;113(2):198-208 - PubMed
  19. Circulation. 2001 Mar 20;103(11):1522-8 - PubMed
  20. J Surg Res. 2005 Jan;123(1):40-8 - PubMed
  21. Circ Res. 1999 May 28;84(10):1223-33 - PubMed
  22. Am J Cardiol. 2003 Nov 1;92(9):1129-32 - PubMed
  23. Mol Cell Biochem. 2002 Sep;238(1-2):145-50 - PubMed
  24. J Clin Endocrinol Metab. 2013 Aug;98(8):3221-8 - PubMed
  25. Atherosclerosis. 2003 Oct;170(2):205-11 - PubMed
  26. BMC Nephrol. 2013 Oct 10;14:219 - PubMed
  27. J Am Coll Cardiol. 2002 Jan 2;39(1):96-101 - PubMed
  28. PLoS One. 2012;7(12):e48851 - PubMed
  29. J Mol Cell Cardiol. 2004 Jan;36(1):57-66 - PubMed
  30. J Thorac Cardiovasc Surg. 2009 Jul;138(1):196-9 - PubMed
  31. Curr Atheroscler Rep. 2009 Mar;11(2):131-8 - PubMed
  32. Ther Adv Musculoskelet Dis. 2014 Apr;6(2):48-57 - PubMed
  33. Mediators Inflamm. 2013;2013:437123 - PubMed
  34. Curr Atheroscler Rep. 2009 May;11(3):206-13 - PubMed
  35. Acta Orthop Scand. 1993 Oct;64(5):553-6 - PubMed
  36. Am J Pathol. 2001 Jul;159(1):321-7 - PubMed
  37. J Am Coll Cardiol. 1997 Mar 1;29(3):630-4 - PubMed
  38. Cardiology. 2012;121(1):20-6 - PubMed
  39. Curr Opin Lipidol. 2007 Oct;18(5):483-91 - PubMed
  40. Circulation. 1994 Aug;90(2):844-53 - PubMed
  41. Ann Endocrinol (Paris). 2011 Oct;72 Suppl 1:S15-22 - PubMed
  42. J Mol Cell Cardiol. 2009 Apr;46(4):526-35 - PubMed
  43. J Heart Valve Dis. 2010 Jul;19(4):459-65 - PubMed
  44. J Heart Valve Dis. 2014 Jan;23(1):55-65 - PubMed
  45. J Surg Res. 2010 Sep;163(1):12-7 - PubMed
  46. J Clin Endocrinol Metab. 2012 Jun;97(6):2027-32 - PubMed
  47. Circulation. 2008 Dec 9;118(24):2555-62 - PubMed
  48. J Intern Med. 2011 Nov;270(5):452-60 - PubMed
  49. Am J Pathol. 2010 Nov;177(5):2399-410 - PubMed
  50. J Am Heart Assoc. 2012 Dec;1(6):e002261 - PubMed
  51. Circulation. 2007 Feb 27;115(8):949-52 - PubMed
  52. Arthritis Rheum. 2009 Apr;60(4):1102-11 - PubMed
  53. Ann Thorac Surg. 2003 Feb;75(2):457-65; discussion 465-6 - PubMed
  54. Circulation. 2008 Jan 22;117(3):411-20 - PubMed
  55. Regul Pept. 2011 Jan 17;166(1-3):76-82 - PubMed
  56. Nephrol Dial Transplant. 2005 Aug;20(8):1676-85 - PubMed
  57. Circulation. 2006 Oct 17;114(16):1703-12 - PubMed
  58. J Thorac Cardiovasc Surg. 2012 Jul;144(1):256-62 - PubMed
  59. EPMA J. 2011 Mar;2(1):91-105 - PubMed
  60. J Microsc. 2011 Mar;241(3):282-90 - PubMed
  61. Eur Heart J. 2014 Apr;35(16):1041-50 - PubMed
  62. Circ Res. 1994 Jul;75(1):181-9 - PubMed
  63. N Engl J Med. 2008 May 15;358(20):2148-59 - PubMed
  64. J Heart Valve Dis. 2010 Jul;19(4):441-52 - PubMed
  65. Eur Heart J. 2005 Jul;26(13):1333-41 - PubMed
  66. Nephrol Dial Transplant. 2006 Aug;21(8):2144-51 - PubMed
  67. Cardiovasc Pathol. 2000 Sep-Oct;9(5):281-6 - PubMed

Publication Types